Androgen deprivation therapy for prostate cancer: current status and future prospects.
about
RhoA as a mediator of clinically relevant androgen action in prostate cancer cellsLigand-specific dynamics of the androgen receptor at its response element in living cellsCasodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression modelInvolvement of the Androgen and Glucocorticoid Receptors in Bladder CancerMedical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantIdentification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen ReceptorAdverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic ReviewPCaAnalyser: a 2D-image analysis based module for effective determination of prostate cancer progression in 3D cultureNuclear receptor expression defines a set of prognostic biomarkers for lung cancerChemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer.C/EBPalpha redirects androgen receptor signaling through a unique bimodal interactionExosomes in prostate cancer: putting together the pieces of a puzzle.Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosisNovel biomarkers for prostate cancer including noncoding transcripts.Transcription factors involved in prostate gland adaptation to androgen deprivation.Therapeutic Implications of Black Seed and Its Constituent Thymoquinone in the Prevention of Cancer through Inactivation and Activation of Molecular Pathways.Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cellsEffects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cellsIdentification of a clinically relevant androgen-dependent gene signature in prostate cancerHedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progressionVascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.The chicken ovalbumin upstream promoter-transcription factor II negatively regulates the transactivation of androgen receptor in prostate cancer cells.Androgen and its receptor promote Bax-mediated apoptosisHormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements.Androgen modulation of coregulator expression in prostate cancer cells.Surgical stress delays prostate involution in mice.Cognitive effects of hormone therapy in men with prostate cancer: a reviewInhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).Mathematical modeling of prostate cancer progression in response to androgen ablation therapy.Androgen deprivation induces rapid involution and recovery of human prostate vasculaturePrognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapyMass spectrometry-based expression profiling of clinical prostate cancer.Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer.Structure-based virtual screening and identification of a novel androgen receptor antagonist.ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.
P2860
Q24618899-FF24F342-09AB-47AC-B4B6-BB1A24BB483AQ24681534-747EE851-C7A5-49EA-BF4A-C16F8709D2F5Q24795055-16CD545B-49A8-4024-A0CA-83437BC6E107Q26782760-E69107CB-AFF5-4CF4-8FCF-F442DF862FA8Q26851177-1A3D66AE-D943-4C2F-8FF8-B3778C4DCB7CQ27659041-4E054107-8803-4E67-BB7E-13E3ADD461FDQ28069186-D140EDD8-E8E4-4F9B-A109-CFB980795B11Q28535321-0F150964-20C9-43D4-8C64-7208C856A660Q28744237-9F780F87-3E11-4620-ADAF-2330AA21A181Q30245022-A1042651-9086-4BF6-9137-FF2BCB19468AQ30393012-C45130C2-BEF5-4258-A34B-AF41168906D9Q30446961-58F13853-886A-4A1C-A4F3-5173F20891D4Q33357387-08E8ED94-5083-4B2C-BC47-054C4DBC9E2CQ33363331-7E07D822-8FF8-4F36-9411-5ED385DCFFA5Q33515231-859CF35C-B131-4E21-B1E9-6695E01FC668Q33699091-69DD5E9D-858B-492C-A609-5A74C9632A8BQ33736242-3DF5B5F9-E589-408D-A0EE-B9A1B4E46753Q33761619-B2795ABE-A12E-4889-BF4C-B02D1DD8BDECQ33775717-9EEE5FEB-A35C-46CB-AB25-DB5CC36E66C8Q33793491-C992484A-D9B2-4C14-BC76-A0C53F916AADQ33803926-3679ECCA-78D6-479F-B390-22157A39EB2DQ33821752-D138AC3F-88BF-499A-9F54-5B497389B027Q33864161-70B4DAF2-9056-4E73-A8BE-F76ACECFC7E1Q34077384-79C09823-40AD-4F87-BE7B-76992A6BEE84Q34279214-1AE99605-CF04-4AC1-85B2-5273B31A3BBCQ34473887-2690FBB3-C770-4F03-A181-46A0279E42E0Q34519663-D4E31BA6-3C69-4C88-9A3B-108EF78DB52EQ34712118-BC6B77B2-B503-4EB6-87AB-6E7CA251ACEBQ34928162-05D46746-05AC-4E3A-8049-357BC94EC1C2Q35040157-F232BB00-6BED-49D3-8AB5-F5EE68EAC221Q35098762-C4ACDAA0-361F-4E96-A51B-9E81B0947264Q35551899-A25AB9FA-2A3A-4656-A668-1A2D31C0274EQ35554014-A73F98FA-D1DF-4E4B-BB71-4DDE5E782684Q35621205-8E392847-CB21-475A-A98A-9FC1E071B51BQ35760385-FC1AC4FC-5CE1-4175-9DEF-DCDA8DF81F56Q35965415-D19BB481-F132-4D34-A931-3B1515317757Q36032608-F631939E-E0AE-439F-9CD7-28DAFCB12E3AQ36113804-38F59291-443B-4C62-9238-3C9C3E5D5E39Q36216496-22DC07DA-E27D-4C21-B74C-3CCFB16AD33EQ36226980-673707DE-D5D5-402D-BF00-4C8D8DFBCE24
P2860
Androgen deprivation therapy for prostate cancer: current status and future prospects.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@ast
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@en
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@nl
type
label
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@ast
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@en
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@nl
prefLabel
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@ast
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@en
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@nl
P2093
P2860
P356
P1433
P1476
Androgen deprivation therapy for prostate cancer: current status and future prospects.
@en
P2093
Chawnshang Chang
Edward M Messing
Hiroshi Miyamoto
P2860
P304
P356
10.1002/PROS.20115
P577
2004-12-01T00:00:00Z